Mani Sharma, SVP, Group Controller and Head of Global Finance Services at AstraZeneca PLC, filed a Form 4 on September 11, 2026, disclosing two acquisitions of ordinary shares in August and September 2026.

Key Highlights

  • Reporting person: Mani Sharma, identified as SVP, Group Controller and Head of Global Finance Services at AstraZeneca PLC (NASDAQ:AZN)
  • First transaction (08/08/2026): Acquisition of 20.233 ordinary shares at $160.57 per share via automatic dividend reinvestment under the Issuer's Restricted Share Plan
  • Second transaction (09/08/2026): Acquisition of 1 ordinary share at $162.60 per share pursuant to the Issuer's Share Incentive Plan
  • Beneficial ownership following transactions: 19,288.6989 ordinary shares held directly
  • Currency conversion: Both prices were converted from British pounds sterling to U.S. dollars using Federal Reserve published rates

Sharma's Share Acquisitions Under AstraZeneca Equity Plans

According to the filing, the first transaction on August 8, 2026 involved the acquisition of 20.233 ordinary shares at a reported price of $160.57, reflecting automatic reinvestment of dividends accrued during the holding period of AstraZeneca's Restricted Share Plan. The filing states the original price was GBP118.96, converted at a rate of GBP1.0000 to $1.3498 as published by the Board of Governors of the Federal Reserve System on August 7, 2026. The filing further notes that "the dividend equivalent units will vest and be released to the Officer at the end of the three year holding period."

The second transaction, dated September 8, 2026, involved the acquisition of 1 ordinary share at $162.60 under the Issuer's Share Incentive Plan. The filing states the original price was GBP120.26, converted at a rate of GBP1.0000 to $1.3521 as published by the Federal Reserve on September 4, 2026. Both transactions were coded as purchases (Code "P" and Code "A," respectively) and resulted in directly held beneficial ownership of 19,288.6989 ordinary shares following the reported transactions, according to the filing.

The Form 4 was filed individually by Sharma as a single reporting person and was signed on September 11, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

AstraZeneca officer Mani Sharma disclosed two acquisitions of ordinary shares under company equity plans in August and September 2026, resulting in direct beneficial ownership of 19,288.6989 ordinary shares, according to the Form 4 filed September 11, 2026.